Share
News
1 - 1 of 1 news items
-
23 August 2011 /Side effects and trials
Commission guidance on adverse reactions from clinical trials (CT3) has been changed
The EU Commission has updated its guidance on adverse reactions arising from clinical trials, known as CT3. In future, CT3 will also include the previous Eudravigilance guidance - clinical trial module (CT4) - as well as the Q&A document regarding adverse reaction reports in clinical trials.
